Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02978404 : Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Men and women, = 18 years of age

2. Willing and able to give written informed consent

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days
prior to registration

4. Radiation Therapy Oncology Group (RTOG) neurological function score of 0-1 within 28
days prior to registration

5. Histologic diagnosis of NSCLC OR ccRCC

6. Stage IV cancer with brain metastases (Patients may have untreated primary disease)

7. Presenting with previously un-irradiated brain metastasis (10 cc maximum volume of
brain disease based on the diagnostic screening MRI done within 28 days of
registration))

8. Measurable/evaluable brain disease

9. Having received less than 4 lines of prior systemic treatments

10. Ability to be treated with either gamma knife or a linear accelerator based
radiosurgery system

11. Ability to complete neurocognitive exams without assistance

12. Ability to complete QOL questionnaires with or without assistance

13. Screening laboratory values must meet the following criteria and should be obtained
within 28 days prior to registration:

- White Blood Cell (WBC) = 2000/uL

- Absolute Neutrophil Count (ANC) = 1.5 x 109/L

- Platelets= 100 x 109/L

- Hemoglobin = 90 g/L (may be transfused)

- Serum creatinine = 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance = 50
ml/min (calculated -cockcroft-Gault)

- Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =3 x ULN without
liver metastasis,= 5 x ULN with liver metastases

- Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome, who can have
total bilirubin < 3.0 mg/dL)

14. Women of childbearing potential (WOCBP) must use appropriate method(s) of
contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (28
days plus the time required for Nivolumab to undergo five half-lives) after the last
dose of investigational drug

15. Women of childbearing potential must have a negative serum or urine pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
start of Nivolumab

16. Women must not be breastfeeding

17. Men who are sexually active with WOCBP must use any contraceptive method with a
failure rate of less than 1% per year. Men receiving Nivolumab and who are sexually
active with WOCBP will be instructed to adhere to contraception for a period of 31
weeks after the last dose of Nivolumab product. Women who are not of childbearing
potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men
do not require contraception).

Exclusion Criteria:

1. Brain metastasis in the brainstem

2. Patients who experienced prior seizures are eligible, however patients should not have
had a seizure within 7 days of registration without the use of corticosteroids.

3. All other cancer histology other than NSCLC or ccRCC

4. Patients who cannot undergo MRI

5. Active, known or suspected autoimmune disease. Subjects are permitted to enroll if
they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to
autoimmune condition only requiring hormone replacement, psoriasis not requiring
systemic treatment, or conditions not expected to recur in the absence of an external
trigger

6. Patients with a condition requiring systemic treatment with either corticosteroids
including steroids used for treating peritumoral edema (> 10 mg daily prednisone
equivalents) or other immunosuppressive medications within 14 days of study drug
administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg
daily prednisone equivalents are permitted in the absence of active autoimmune
disease.

7. Drugs with a predisposition to hepatoxicity should be used with caution in patients
treated with Nivolumab-containing regimen

8. Any underlying medical or psychiatric condition, which in the opinion of the
investigator will make the administration of Nivolumab hazardous or obscure the
interpretation of AEs, such as a condition associated with frequent diarrhea.

9. History of prior treatment with a CTLA-4, PD-1 or PD-L1 inhibitor, CD137 agonist, or
anti-PD-L2.

10. Concomitant therapy with any of the following: IL-2, interferon, or other non-study
immunotherapy regimens; immunosuppressive agents; other investigation therapies

11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (eg, infectious) illness.

12. Known history of hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
ribonucleic acid (HCV antibody) indicating acute or chronic infection

13. History of allergy to study drug components.

14. Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS).
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02978404      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740